PWM
ADCT icon

Perigon Wealth Management’s ADC Therapeutics ADCT Stock Holding History

Perigon Wealth Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4K Buy
+10,656
New +$31.1K ﹤0.01% 1432

Other funds holding ADCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SCTC
Sanibel Captiva Trust Company Sanibel, Florida $4.02B AUM 34.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
RWP
Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return

Perigon Wealth Management's ADCT Position: Q2 2026 in Review

Perigon Wealth Management opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 10,656 shares worth $11.4K. The stake represents ﹤0.01% of the portfolio and ranks #1432 among its holdings.

38 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Perigon Wealth Management held 10,656 shares of ADC Therapeutics worth $11.4K as of Q2 2026.
  • ADC Therapeutics was a new Perigon Wealth Management position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Perigon Wealth Management's portfolio in Q2 2026, its #1432 holding.
  • 38 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Perigon Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.